Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Rigosertib Oral in Transfusion Dependent Lower Risk Myelodysplastic Syndromes (LR-MDS): Optimization of Dose and Rate of Transfusion Independence (TI) or Transfusion Reduction (TR) in a Single-Arm Phase 2 Study

Azra Raza, MD, Aref Al-Kali, MD, Raoul Tibes, MD PhD, Gary Spitzer, MD, Manila Gaddh, MD, Benjamin Tycko, MD PhD, Sangmin Lee, MD, Naomi Galili, PhD, Abdullah Mahmood Ali, PhD, John G. Mears, MD, Siddhartha Mukherjee, MD PhD, Ryan Shelton, BS, Steven M. Fruchtman, MD, Michael E. Petrone, MD MPH, Patrick S. Zbyszewski, MBA, Mark Lawrence Heaney, MD PhD

Blood (2017) 130 (Supplement 1): 1689.

https://doi.org/10.1182/blood.V130.Suppl_1.1689.1689

Published: 2017

Journal Articles

Dynamics of Telomere Length Reflect the Clonal Suppression Seen with the Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia

Monika Haubitz, PhD, Elisabeth Oppliger Leibundgut, PharmD, Ingrid Helsen, Dania Hiltbrunner, Bart Burington, PhD, Oliver G. Ottmann, MD, Gary Spitzer, MD, Olatoyosi Odenike, MD, Michael A McDevitt, MD PhD, Alexander Röth, MD, David S. Snyder, MD, Gabriela M. Baerlocher, MD

Blood (2016) 128 (22): 1938.

https://doi.org/10.1182/blood.V128.22.1938.1938

Published: 2016

Journal Articles

Dynamics of Mutations in Patients with ET Treated with Imetelstat

Elisabeth Oppliger Leibundgut, PharmD, Monika Haubitz, PhD, Bart Burington, PhD, Oliver G. Ottmann, MD, Gary Spitzer, MD, Olatoyosi Odenike, MD, Michael A McDevitt, MD PhD, Alexander Roeth, MD, David S. Snyder, MD, Gabriela M. Baerlocher, MD

Blood (2015) 126 (23): 57.

https://doi.org/10.1182/blood.V126.23.57.57

Published: 2015

Journal Articles

Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression

Eric D. Jacobsen, Jeff P. Sharman, Yasuhiro Oki, Ranjana H. Advani, Jane N. Winter, Celeste M. Bello, Gary Spitzer, Maria Corinna Palanca-Wessels, Dana A. Kennedy, Pamela Levine, Jing Yang, Nancy L. Bartlett

Blood (2015) 125 (9): 1394–1402.

https://doi.org/10.1182/blood-2014-09-598763

Published: 2015

Includes: Supplemental data

Journal Articles

A Phase I Trial Of Anti-KIR Monoclonal Antibody IPH2101 and Lenalidomide For Multiple Myeloma

Don M. Benson, Jr., MD, PhD, Adam D Cohen, MD, Craig C Hofmeister, MD, Munshi C Nikhil, MD, Sundar Jagannath, MD, Yvonne A Efebera, MD, Gary Spitzer, MD, Robert Zerbib, Pascale Andre, PhD, Shawna Oxier, Michael A. Caligiuri, MD

Blood (2013) 122 (21): 3181.

https://doi.org/10.1182/blood.V122.21.3181.3181

Published: 2013

Journal Articles

Oral Rigosertib (ON 01910.Na) Treatment Produces An Encouraging Rate Of Transfusion Independence In Lower Risk Myelodysplastic Syndromes (MDS) Patients; A Genomic Methylation Profile Is Associated With Responses

Azra Raza, MD, Benjamin Tycko, M.D., Ph.D., Sangmin Lee, MD, Naomi Galili, Ph.D., Abdullah Ali, Andrew Eisenberger, MD, John G. Mears, MD, Aref Al-Kali, MD, Raoul Tibes, MD, PhD, Gary Spitzer, MD, Francois Wilhelm, MD, PhD., Siddhartha Mukherjee, MD, PhD

Blood (2013) 122 (21): 2745.

https://doi.org/10.1182/blood.V122.21.2745.2745

Published: 2013

Journal Articles

Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma

Matthew J. Matasar, Myron S. Czuczman, Maria Alma Rodriguez, Michael Fennessy, Thomas C. Shea, Gary Spitzer, Izidore S. Lossos, Mohamed A. Kharfan-Dabaja, Robin Joyce, Luis Fayad, Kristen Henkel, Qiming Liao, Klaus Edvardsen, Roxanne C. Jewell, Doug Fecteau, Rajendra P. Singh, Steen Lisby, Craig H. Moskowitz

Blood (2013) 122 (4): 499–506.

https://doi.org/10.1182/blood-2012-12-472027

Published: 2013

Journal Articles

Imetelstat Rapidly Induces and Maintains Substantial Hematologic and Molecular Responses in Patients with Essential Thrombocythemia (ET) Who Are Refractory or Intolerant to Prior Therapy: Preliminary Phase II Results

Gabriela M. Baerlocher, MD, Elisabeth Oppliger Leibundgut, PharmD, Christina Ayran, Martha Blaney, PharmD, Bart Burington, Ph.D, Dianne Morfeld, Olatoyosi Odenike, MD, Oliver Ottman, MD, Anita Reddy, PhD, Alexander Roeth, MD, Gary Spitzer, MD, Monic J. Stuart, MD, MPH, Srdan Verstovsek, MD, PhD, David S. Snyder, MD

Blood (2012) 120 (21): 179.

https://doi.org/10.1182/blood.V120.21.179.179

Published: 2012

Journal Articles

A Phase I Trial of the Anti-Inhibitory KIR Antibody, IPH2101, and Lenalidomide in Multiple Myeloma: Interim Results

Don M. Benson, Jr., MD, PhD, Adam D Cohen, MD, Nikhil C. Munshi, MD, Sundar Jagannath, MD, Gary Spitzer, MD, Craig C. Hofmeister, MD, Robert Zerbib, Pascale Andre, PhD, Yvonne A Efebera, M.D., Shawna Oxier, Michael A. Caligiuri, M.D.

Blood (2012) 120 (21): 4058.

https://doi.org/10.1182/blood.V120.21.4058.4058

Published: 2012

Journal Articles

A Phase II Study of Ofatumumab in Combination with ICE or DHAP Chemotherapy in Relapsed or Refractory Aggressive B-Cell Lymphoma Prior to Autologous Stem Cell Transplantation (ASCT)

Matthew J. Matasar, MD, MS, Myron S. Czuczman, MD, Maria Alma Rodriguez, MD, Michael Fennessy, BSc, PhD, Thomas C. Shea, MD, Gary Spitzer, MD, Izidore S Lossos, MD, Mohamed A. Kharfan-Dabaja, MD, Robin Joyce, MD, Luis Fayad, MD, Qiming Liao, PhD, Klaus Edvardsen, MD, PhD, Steen Lisby, MD, DMSc, Craig H. Moskowitz, MD

Blood (2011) 118 (21): 957.

https://doi.org/10.1182/blood.V118.21.957.957

Published: 2011

Journal Articles

Results of a Phase II Open-Label Trial of Bortezomib in Patients with Multiple Myeloma Who Have Undergone High-Dose Melphalan Therapy Followed by Autologous Peripheral Blood Stem Cell Transplantation and Failed to Achieve a Complete Response

Robert M. Rifkin, MD, Gary Spitzer, MD, Andrew Greenspan, MD, John F. Schwerkoske, MD, Romeo A. Mandanas, MD, FACP, Joe Stephenson, MD, George T. Kannarkat, Feng Zhan, PhD, Lina Asmar, PhD, Roy Beveridge, MD

Blood (2008) 112 (11): 2780.

https://doi.org/10.1182/blood.V112.11.2780.2780

Published: 2008

Journal Articles

Results of a Randomized Phase II Trial of Pegfilgrastim Versus Filgrastim To Treat Neutropenia Post-Autologous Peripheral Blood Stem Cell Transplant (PBSCT) in Patients with Non-Hodgkin’s Lymphoma (NHL).

Robert Rifkin, MD, Roy Beveridge, MD, Gary Spitzer, MD, Gregory Orloff, MD, Romeo Mandanas, MD, Dean McGaughey, MD, Mark Brunvand, MD, Feng Zhan, PhD, Kristi A. Boehm, MS, Lina Asmar, PhD

Blood (2007) 110 (11): 4936.

https://doi.org/10.1182/blood.V110.11.4936.4936

Published: 2007

Journal Articles

Interim Analysis of a Phase II Trial of Bortezomib in Patients with Multiple Myeloma Who Failed To Achieve a Complete Response to Autologous Peripheral Blood Stem Cell Transplantation.

Robert M. Rifkin, MD, Roy A. Beveridge, MD, Mark W. Brunvand, MD, Gary Spitzer, MD, Boehm A. Kristi, MS, Mary Ann Rauch, BS, Feng Zhan, PhD, Lina Asmar, PhD

Blood (2005) 106 (11): 5176.

https://doi.org/10.1182/blood.V106.11.5176.5176

Published: 2005

Journal Articles

A Randomized Phase II Study of Xcellerated T Cells™ with or without Prior Fludarabine Therapy in Patients with Relapsed or Refractory Multiple Myeloma.

James R. Berenson, MD, Ivan M. Borrello, MD, Ravi Vij, MD, Asad Bashey, MD, Thomas Martin, MD, Ralph V. Boccia, MD, Ann Mohrbacher, MD, Aleksandra Simic, MD, Gary Spitzer, MD, Jayne Meyer, Ron J. Berenson11, MD, Mark W. Frohlich12, MD

Blood (2004) 104 (11): 2410.

https://doi.org/10.1182/blood.V104.11.2410.2410

Published: 2004

Journal Articles

Lymphoblastic Leukemia with Marked Eosinophilia: A Report of Two Cases

Gary Spitzer, M.D., O. Margaret Garson, M.D.

Blood (1973) 42 (3): 377–384.

https://doi.org/10.1182/blood.V42.3.377.377

Published: 1973

NARROW

Rigosertib Oral in Transfusion Dependent Lower Risk Myelodysplastic Syndromes (LR-MDS): Optimization of Dose and Rate of Transfusion Independence (TI) or Transfusion Reduction (TR) in a Single-Arm Phase 2 Study

Dynamics of Telomere Length Reflect the Clonal Suppression Seen with the Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia

Dynamics of Mutations in Patients with ET Treated with Imetelstat

Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression

A Phase I Trial Of Anti-KIR Monoclonal Antibody IPH2101 and Lenalidomide For Multiple Myeloma

Oral Rigosertib (ON 01910.Na) Treatment Produces An Encouraging Rate Of Transfusion Independence In Lower Risk Myelodysplastic Syndromes (MDS) Patients; A Genomic Methylation Profile Is Associated With Responses

Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma

Imetelstat Rapidly Induces and Maintains Substantial Hematologic and Molecular Responses in Patients with Essential Thrombocythemia (ET) Who Are Refractory or Intolerant to Prior Therapy: Preliminary Phase II Results

A Phase I Trial of the Anti-Inhibitory KIR Antibody, IPH2101, and Lenalidomide in Multiple Myeloma: Interim Results

A Phase II Study of Ofatumumab in Combination with ICE or DHAP Chemotherapy in Relapsed or Refractory Aggressive B-Cell Lymphoma Prior to Autologous Stem Cell Transplantation (ASCT)

Results of a Phase II Open-Label Trial of Bortezomib in Patients with Multiple Myeloma Who Have Undergone High-Dose Melphalan Therapy Followed by Autologous Peripheral Blood Stem Cell Transplantation and Failed to Achieve a Complete Response

Results of a Randomized Phase II Trial of Pegfilgrastim Versus Filgrastim To Treat Neutropenia Post-Autologous Peripheral Blood Stem Cell Transplant (PBSCT) in Patients with Non-Hodgkin’s Lymphoma (NHL).

Interim Analysis of a Phase II Trial of Bortezomib in Patients with Multiple Myeloma Who Failed To Achieve a Complete Response to Autologous Peripheral Blood Stem Cell Transplantation.

A Randomized Phase II Study of Xcellerated T Cells™ with or without Prior Fludarabine Therapy in Patients with Relapsed or Refractory Multiple Myeloma.

Lymphoblastic Leukemia with Marked Eosinophilia: A Report of Two Cases

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only